Summary
The protein coded by the oncogene c-myc, p62c-myc, was measured using monoclonal antibodies and flow cytometry in nuclei derived from paraffin-wax sections of transitional cell carcinomas of the human bladder. Superficial disease (stages pTa and pT1) which did not recur within 5 years of diagnosis had significantly higher oncoprotein levels than those which did recur or were muscle-invasive (stage pT2 or greater) at presentation (P<0.01). These preliminary findings indicate that oncoprotein levels might have prognostic significance for bladder cancer.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Bishop JM (1987) The molecular genetics of cancer. Science 235:305–311
Evan GI, Hancock DC (1985) Studies on the interaction of the human c-myc protein with cell nuclei: p62c-myc as a member of a discrete subset of nuclear proteins. Cell 43:253–261
Evan G, Lewis GK, Ramsay G, Bishop JM (1985) Isolation of monoclonal antibodies specific for human and mouse protooncogene products. Mol Cell Biol 5:3610–3616
Forgacs IC, Sunderesan V, Evan G, Wight DGD, Neale G, Hunter JO, Watson JV (1986) Abnormal expression of c-myc oncogene product in dysplasia and neoplasia associated with ulcerative colitis. Gut 27:A1285
Hedley DW, Friedlander MI, Taylor IW, Rugg CA, Musgrove EA (1983) Method for analysis of cellular DNA content of paraffin-embedded pathological material using flow cytometry. J Histochem Cytochem 31:1333–1335
Hendy-Ibbs P, Cox H, Evan GI, Watson JV (1987) Flow cytometric quantitation of DNA and c-myc oncoprotein in archival biopsies of uterine cervix neoplasia. Br J Cancer 55:215–282
Kelly K, Cochran BH, Stiles CD, Leder P (1984) The regulation of c-myc by growth signals. Curr Top Microbiol Immunol 113:117–126
Lum BL (1983) Intravesical chemotherapy of superficial bladder cancer. Recent Results Cancer Res 85:3–36
Rabbitts PH, Watson JV, Lamond A, Fischer W, Forester A, Stinton MA, Evan GI, Atherton E, Sheppard RC, Rabbitts TH (1985) Metabolism of c-myc gene products: c-myc mRNA and protein expression in the cell cycle. EMBO J 4:2009–2015
Sikora K, Evan G, Stewart J, Watson JV (1985) Detection of the c-myc oncogene product in testicular cancer. Br J Cancer 52:171–176
Sikora K, Chan S, Evan G, Gabra H, Markham N, Stewart J, Watson JV (1987) c-myc oncogene expression in colorectal cancer. Cancer 59:1289–1295
Stewart J, Evan GI, Watson JV, Sikora KE (1986) Detection of the c-myc oncogene product in colonic polyps and carcinomas. Br J Cancer 53:1–6
Studzinski GP, Brulei ZS, Feldman SC, Watt RA (1986) Participation of c-myc protein in DNA synthesis of human cells. Science 234:467–470
Watson JV (1980) Enzyme kinetic studies in cell populations using fluorogenic substrates and flow cytometric techniques. Cytometry 1:143–151
Watson JV (1985) A method for improving light collection by 600% from square cross section flow cytometry chambers. Br J Cancer 51:433–435
Watson JV (1986) Oncogenes, cancer and analytical cytology. Cytometry 7:400–410
Watson JV, Sikora KE, Evan GI (1985) A simultaneous flow cytometric assay for c-myc oncoprotein and cellular DNA in nuclei from paraffin embedded material. J Immunol Methods 83:179–192
Watson JV, Stewart J, Ritson A, Evan GI, Sikora EK (1986) The clinical significance of flow cytometric c-myc oncoprotein quantitation in testicular cancer. Br J Cancer 53:331–337
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Masters, J.R.W., Vesey, S.G., Munn, C.F. et al. c-myc oncoprotein levels in bladder cancer. Urol. Res. 16, 341–344 (1988). https://doi.org/10.1007/BF00256039
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00256039